Neues Kürzel NWBO neuer Schwung? - 500 Beiträge pro Seite (Seite 2)

[guntis]

dann schicken wir ihnen den Arzt vorbei

damits a bisserl schneller geht

[prom]

Antwort auf Beitrag Nr.: 32.769.584 von guntis am 14.12.07 19:40:25

weis jemand wann der Weihnachtsbonus zugeteilt wird

[guntis]

Antwort auf Beitrag Nr.: 32.804.611 von prom am 18.12.07 16:28:10

vermutlich am Freitag

[guntis]

heute gibts mal eine News - ist die nun gut oder schlecht

komme leider mit der Übersetzung nicht klar (Google)

kann mich mal einer aufklären um was es da genau geht

danke

guntis

Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics

BETHESDA, Md., Dec 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:northwest biotherapeutics in com new
News, chart, profile, more
Last: 2.37-0.01-0.42%

2:10pm 12/19/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
NWBO 2.37, -0.01, -0.4%) , Northwest Biotherapeutics ("NWBT") announced today that Lonza Group AG has withdrawn all claims of patent infringement involving NWBT's DCVax(R)-Brain product and other NWBT DCVax(R) products other than DCVax(R)-Prostate. Lonza had alleged that NWBT's DCVax(R) cancer vaccine products infringed certain gene expression technology patents held by Lonza. However, as could be seen from publicly available information sources -- available before the Lonza lawsuit was filed as well as since then -- NWBT does not use any gene modification or gene expression system in its DCVax(R) products.
Lonza filed suit against NWBT on July 27, 2007, in the U.S. District Court for the District of Delaware, alleging that all of NWBT's DCVax(R) products infringed certain gene expression patents held by Lonza. After the filing of a lawsuit, a period of up to 120 days is allowed for service of the complaint on the party sued. In this case, Lonza chose not to serve NWBT throughout the entire 120-day period. As a result, the filing of an answer and counterclaims by NWBT was delayed until this extended period had expired. During the 120-day period, NWBT provided further information to Lonza -- in addition to the already publicly available information sources -- showing that NWBT's DCVax(R) products do not use any gene expression system. When Lonza still chose not to withdraw its complaint, NWBT filed an answer and counterclaims as soon as the 120-day period expired, denying all infringement claims by Lonza, and seeking recovery for violation of the Delaware Deceptive Trade Practices Act, unfair competition, tortious interference with prospective contractual relations, and abuse of process, including, among other things, treble damages and punitive damages. Following NWBT's filing of this answer and counterclaim, Lonza agreed with NWBT to the dismissal of both Lonza's entire complaint and NWBT's answer and counterclaims in Delaware.
However, simultaneously, Lonza filed a new, second lawsuit in the U.S. District Court for the District of Maryland, again alleging infringement by NWBT and potentially including again up to the full range of NWBT's DCVax(R) products. The new second lawsuit removed explicit references to DCVax(R) products other than DCVax(R)-Prostate, but still claimed that not only DCVax(R)-Prostate but also "other infringing products or technologies" of NWBT infringed Lonza's gene expression patents. In light of the information available to Lonza both from public sources and privately from NWBT, NWBT demanded that Lonza remove all allegations from the second complaint in Maryland relating to any product other than DCVax(R)-Prostate.
Following NWBT's demand, Lonza has withdrawn from its Maryland complaint all allegations of infringement by NWBT products other than DCVax(R)-Prostate. This withdrawal was put into effect by Lonza's filing of an Amended Complaint in the U.S. District Court in Maryland on December 13, 2007 that accuses only DCVax(R)-Prostate of infringement (and asserts related state law claims).
Thus, the only remaining allegation by Lonza of infringement now relates to NWBT's DCVax(R)-Prostate product. NWBT strongly disputes that its activities surrounding DCVax(R)-Prostate constitute any infringement by NWBT, and NWBT intends to fight the remaining Lonza claims vigorously.
The only use of a gene expression system ever connected in any way, even indirectly, with any NWBT product has been the use by an unrelated third-party manufacturer of a gene expression system to produce two batches of recombinant PSMA protein for NWBT nine years ago and six years ago, respectively. The third party manufacturer chose the gene expression system it used, and was the only party who used that expression system in any connection with NWBT's product. NWBT did not use, nor has it ever used, Lonza's expression system. NWBT contracted to receive, and did receive, two batches of recombinant PSMA protein from the manufacturer. The PSMA protein that NWBT received was used in the manufacture of only one NWBT product: DCVax(R)-Prostate. The lots of DCVax(R)-Prostate product which involved these two batches of PSMA protein were used solely for early clinical trials in 1999 and 2000, and briefly in 2002, in the US. No other recombinant protein has ever been used to manufacture any other DCVax(R) product.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.
For further information, please visit the company web site at http://www.nwbio.com.
Disclaimer
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include statements regarding the progress and NWBT's expectations concerning the pending litigation with Lonza Group AG. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as uncertainties concerning the progress and ultimate outcome of the litigation involving Lonza Group AG. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.

[Tiefstseetaucher]

Antwort auf Beitrag Nr.: 32.822.390 von guntis am 20.12.07 09:11:58

Also nach dem ersten kurzen Überfliegen der Meldung würde ich sagen, dass Lonza einen Teil seiner Patentklagen gegen NWBO zurückzieht und nur noch den Teil der Klage, der sich auf DVax Prostata bezieht, aufrecht erhält.

Größere Auswirkungen dürfte das m.E. allerdings nicht haben. Besser wäre es natürlich gewesen, die hätten alle Klagepunkte zurückgezogen. Habe allerdings keine Ahnung, ob die Patentklage irgendwie berechtigt ist oder nicht bzw. Erfolgschancen hat oder nicht.


Gruß

Tiefstseetaucher

[guntis]

Antwort auf Beitrag Nr.: 32.822.390 von guntis am 20.12.07 09:11:58

ach ich Dödel

das wichtigste Wort hat mir Google falsch übersetzt

withdraw - abziehen, annulieren, entziehen, zurücknehmen

und ich meinte schon das Gegenteil

dann sollte es doch eine Super News sein

mal schaun was der Kurs heute Nachmittag macht

[guntis]

Antwort auf Beitrag Nr.: 32.822.595 von Tiefstseetaucher am 20.12.07 09:29:18

danke

[guntis]

News garen gar nicht mal so schlecht

[guntis]

Antwort auf Beitrag Nr.: 32.827.201 von guntis am 20.12.07 15:34:54

seit wann garen die News

[prom]

Antwort auf Beitrag Nr.: 32.827.258 von guntis am 20.12.07 15:39:25

umsatz gut, kurs schei..

[guntis]

hat schon jemand die heutige News gelesen?

scheint voran zu gehen

aber der burner scheint es nicht zu sein

mal schaun was die Amis meinen

Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
First Patients Enrolled and Being Treated

Last update: 2:00 a.m. EST Dec. 27, 2007Print E-mail RSS Disable Live Quotes

BETHESDA, Md., Dec 27, 2007 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:northwest biotherapeutics in com new
News, chart, profile, more
Last: 2.500.000.00%

3:25pm 12/26/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:

NWBO 2.50, 0.00, 0.0%) (AIM: NWBT; NWBS) ("NWBT") today announced that a Phase I/II clinical trial in at least 30 patients, using DCVax(R)-L for recurrent ovarian cancer, has begun at The University of Pennsylvania Center for Research on Early Detection and Cure of Ovarian Cancer and the Abramson Cancer Center. The first patients have been enrolled and have undergone initial treatment steps in preparation for receiving DCVax(R)-L. The trial involves two sequential studies, and comprises an innovative combination of multiple treatment modalities. DCVax(R)-L forms the cornerstone of the treatment regimen, and is complemented by administration of low doses of certain existing approved drugs to help improve the immune system environment, as well as by adoptive transfer of patients' DCVax(R)-L primed T cells. The principal investigators for the trial are Dr. George Coukos and Dr. Sarah Kim, and the Penn Investigational New Drug ("IND") sponsor is Dr. Carl June. The funding is being provided by the Ovarian Cancer Vaccine Initiative. (See below for more information about this Initiative.)
DCVax(R)-L is a personalized immunotherapy for cancer, which is made from a patient's own dendritic cells (the master cells which initiate and manage the overall immune system response to a disease), and the "antigens" (biomarkers) from the patient's own tumor tissue which has been surgically removed as part of the standard of care. Such immunotherapy is sometimes referred to as a "therapeutic vaccine," as it is designed not to prevent cancer but to treat patients who already have cancer.
In the first study being conducted by NWBT and Penn, patients will first undergo standard surgery to reduce their tumor burden. Patients will then receive limited doses of two existing drugs to improve the immune system environment and modify the tumor vasculature. Cancer researchers have become increasingly focused on the role of tumor vasculature and the tumor microenvironment, as well as the possible role of a certain kind of cells called "regulatory T cells," in causing a patient's immune system to become unresponsive to the patient's tumor, and on the potential importance of modifying these factors in order to achieve robust and durable immune responses against tumors.
Following the preparatory treatments, the patients in this ovarian cancer trial will receive a series of three immunizations with DCVax(R)-L, each two weeks apart, while continuing to receive the low doses of two drugs intended to keep the immune system and the tumor microenvironment in a beneficial condition.
The second study, which will be a follow-on to the first study but covered by a separate IND filing, will compare two treatment arms continuing further with the drug and DCVax(R)-L regimen, and adding the adoptive transfer of DCVax(R)-L primed, and expanded T cells.
By combining multiple diverse treatment modalities, structured around DCVax(R)-L as the cornerstone, this clinical trial is designed to implement evolving research findings on the complex interactions between tumors and the "host" tissues in patients, and evolving findings on the many facets of the immune system and what may be required for effective anti-tumor responses.
The trial is also designed to minimize any potential toxicity for patients. Clinical trial experience to date with DCVax(R)-L products in over 100 treatment cycles in brain cancer patients has shown no toxicity from the DCVax(R)-L treatment (no grade 3 or 4 adverse events). This multi-modal ovarian cancer trial has been designed to maintain this minimal-toxicity approach, by using only low doses of the two drugs complementing DCVax(R)-L for preparatory effects.
The first patients have been enrolled in the study by Dr. George Coukos. Dr. Coukos stated, "this is a very significant event for patients at the University of Pennsylvania and nationwide who are diagnosed with ovarian cancer. We are excited to work with Northwest Biotherapeutics on this cutting edge clinical trial, and to test the DCVax(R) platform on an additional cancer that carries a poor prognosis."
Dr. Carl June, the Penn sponsor on the trial, stated, "the combination of DCVax(R)-L for ovarian cancer with adoptive immunotherapy using T cells primed by DCVax(R)-L is an innovative approach that deserves testing in clinical trials."
"We are very pleased to add Ovarian cancer to the DCVax(R) platform, and to have Dr. George Coukos and Dr. Carl June lead this effort as the principal investigators for this clinical trial," stated Alton Boynton, President and Chief Executive Officer of Northwest Biotherapeutics. "Drs. Coukos and June are world renowned experts in immunotherapy and in ovarian cancer. They are playing a major role in the pioneering of novel cancer treatment strategies -- particularly by combining multiple different therapeutic approaches."
Ovarian cancer is the fourth leading cause of cancer death among women in the U.S. Approximately 22,400 new cases were diagnosed in the U.S. in 2006, and about 15,300 deaths occurred. In the majority of ovarian cancer cases, the disease has already reached late stage, and spread beyond the ovaries, before it is detected and diagnosed. After initial surgical removal of tumors, and treatment with currently available drugs, the median time to disease recurrence is 18 to 20 months. Recurrent disease is considered incurable and usually results in death, even with aggressive chemotherapy treatments. Accordingly, there is a major unmet medical need for new and more effective treatments for ovarian cancer -- especially recurrent ovarian cancer.
The DCVax(R) platform uses a patient's own tumor, surgically removed as part of the standard of care, to prepare a mix of their personal cancer biomarkers. These personal cancer biomarkers are then loaded onto the patient's own dendritic cells (the master cells responsible for starting and managing the body's overall immune response), and injected back into the patient through a simple intra-dermal injection, similar to an insulin shot, at various intervals over a period of up to three years.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.
For further information, please visit the company web site at http://www.nwbio.com.
About the Ovarian Cancer Vaccine Initiative
The Ovarian Cancer Vaccine Initiative (OCVI) is a private philanthropic organization that is funding this NWBT trial at the Hospital of the University of Pennsylvania. Fundraising to underwrite the clinical trial, and translational research that supports it, is actively sought by the OCVI campaign heads and lead donors, Patricia Dunn and Randall Caudill. Donations in cash or stock, which qualify for tax-exemption, may be directed to:

Ovarian Cancer Vaccine Initiative
Account 9078-6137
Schwab Charitable Fund
101 Montgomery Street
San Francisco, CA 94104
http://www.schwabcharitable.org/pdf/contribute.pdf
1-800-746-6137



About the Center for Research on Early Detection and Cure of Ovarian Cancer at the University of Pennsylvania
The Center for Research on Early Detection and Cure of Ovarian Cancer, directed by Dr. George Coukos, is a newly founded Research Center at the University of Pennsylvania. The Center comprises several full time translational and clinical scientists whose focus is to identify new detection methods, develop new therapies, and ultimately prolong and improve the quality of life for women with ovarian cancer.
Recent discoveries at the Center include the beneficial impact of immune response in advanced ovarian cancer; the contribution of inflammatory cells to the tumor vasculature; the role of tumor vasculature and tumor microenvironment in controlling the outcome of antitumor immune response and immune therapy; the identification of novel proteins expressed in ovarian cancer vasculature that can be targeted for early detection and therapy; and the identification of several gene alterations in ovarian cancer including miRNA genes.
The clinical research activities of the Center focus on developing individualized therapy approaches to patients with ovarian cancer, combining surgery and conventional therapy with novel immune therapies. A number of novel immune cellular therapeutic tools are under development in collaboration with the Cell and Vaccine Production Facility at the Abramson Cancer Center, directed by Drs. Carl June and Bruce Levine.
Disclaimer
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the company's ability to raise additional capital, risks related to the company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, whether the Company's products will demonstrate safety and efficacy, and the timely performance of third parties. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward- looking statements. The company assumes no obligation to update any forward- looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.

[glaut-nicht-alles]

http://www.boardcentral.com/search/NWBO/

[guntis]

hier könnte es auch bald mal hoch gehen

[prom]

Antwort auf Beitrag Nr.: 32.981.961 von guntis am 08.01.08 17:01:09

ja, es wird Zeit

[guntis]

Antwort auf Beitrag Nr.: 32.983.245 von prom am 08.01.08 18:29:20

diese Firma gibt es in Wirklichkeit gar nicht

[mitleser]

Was für ein Trauerspiel

[prom]

Antwort auf Beitrag Nr.: 33.191.654 von mitleser am 28.01.08 16:26:33

Schlafen die alle bei NWBO? Werd mal anrufen, oder ist das Telefon schon abgestellt? Fragen über Fragen

[guntis]

Antwort auf Beitrag Nr.: 33.192.613 von prom am 28.01.08 17:45:19

geht heute mit mini Umsätzen hoch

Herr, lass mal eine News erscheinen

[prom]

Antwort auf Beitrag Nr.: 33.204.047 von guntis am 29.01.08 17:24:00

Hab gestern mal angerufen, deshalb steigt der Kurs heute

[prom]

Antwort auf Beitrag Nr.: 33.206.489 von prom am 29.01.08 20:26:24

Habs vergessen, die News wird kommen, Medikament zeigt volle Wirkung

[guntis]

Antwort auf Beitrag Nr.: 33.206.511 von prom am 29.01.08 20:28:42

das können das heute nur Insiderkäufe gewesen sein

[prom]

Antwort auf Beitrag Nr.: 33.208.174 von guntis am 29.01.08 22:44:32

Hier gibt es nur Insider, die Luschen kommen erst bei 10$

[guntis]

Antwort auf Beitrag Nr.: 33.216.195 von prom am 30.01.08 17:13:01

kannst du bitte nochmals anrufen, dann steigt der Kurs morgen wieder

hab heute auch mal eine Mail geschrieben

bin mal gespannt, ob ich ne Antwort bekomme

[guntis]

http://www.rns-pdf.londonstockexchange.com/rns/7695n_-2008-2-11.pdf

[guntis]

Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
Year-end 2007 long-term follow-up data continues to be positive

Last update: 2:00 a.m. EST Feb. 20, 2008Print E-mail RSS Disable Live Quotes

BETHESDA, Md., Feb 20, 2008 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:NWBO
News, chart, profile, more
Last:


Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
NWBO, , ) ("NWBT" or the "Company") today announced the most recent long-term follow-up data, as of year-end 2007, on disease progression and overall survival in patients taking part in its Phase I and Phase I/II clinical trials for newly diagnosed patients with Glioblastoma multiforme ("GBM"), the most aggressive form of brain cancer. The additional data covers the period from April 2007 through year-end 2007. During this time, none of the patients experienced disease progression (recurrence) and only one patient died (at 36.4 months). Thus, the data show that in the 19 clinical trial patients receiving DCVax(R)-Brain in addition to Standard of Care, both the median overall survival and the median time to disease progression (recurrence) are more than twice as long as in patients receiving the Standard of Care for GBM. Dr. Linda Liau, Associate Professor of Neurosurgery and Director of the Malignant Brain Tumor Program at the UCLA School of Medicine ("UCLA"), served as the Principal Investigator for the trial.
Since 2005, the Standard of Care for patients with GBM is surgery followed by a combination of radiation and daily Temodar(R) chemotherapy, and then 6 monthly cycles of Temodar chemotherapy. The studies defining this Standard of Care achieved a median time to progression of 6.9 months and a median overall survival of 14.6 months (Stupp, et. al., N Engl J Med, 352:987, 2005). Further data from UCLA have demonstrated a somewhat longer median time to progression of 8.1 months and median overall survival of 17.0 months in patients with GBM who received Standard of Care.
The year-end 2007 data obtained by the Company concerning the 19 patients from the two trials at UCLA with newly diagnosed GBM continue to be positive, with no patients progressing and only one patient dying (at 36.4 months). Overall, the long-term follow-up data are now as follows:
o 8 of 19 patients are still alive (ranging from 24.5 months to 92
months), with median overall survival in all patients of 33.8 months
(p < 0.0079) (the "p value" measures the likelihood that the observed
clinical effect is due to chance: a 'p' value of 0.0079 means that
there is a less than 1% possibility that the longer survival time of
DCVax(R)-Brain-treated patients is due to chance);

o 5 of the 8 patients who are still alive show no signs of cancer
recurrence, with follow-up time ranging from 41 months to 92 months;

o The median time to progression (i.e. tumor recurrence) is 18.1 months,
compared to 8.1 months for patients treated at UCLA during the same
time period (p = 0.00001);

o 90% of patients have surpassed the Standard of Care median time to
progression of 8.1 months;

o 84% of patients have surpassed the Standard of Care median overall
survival time of 17.0 months;

o To date, 68% of patients receiving DCVax(R)-Brain in addition to
Standard of Care have lived longer than 2 years, 42% have lived longer
than 3 years, and 26% have lived longer than 4 years (48, 54, 57, 62
and 92 months so far);



"Findings such as these, where we are seeing 68% of our DCVax(R)-Brain-treated patients with GBM alive after two years, and 26% alive for more than 4 years (and counting) reinforce our belief that DCVax(R)-Brain may make a significant difference in the lives of patients with GBM," stated Dr. Alton L. Boynton, President and Chief Executive Officer of Northwest Biotherapeutics. "We believe that the results to date are particularly striking, and we plan to give patients continued booster injections at 3 month intervals. We believe that these booster injections will further enhance and sustain the patient's immune response in attacking the cancer and preventing or delaying its recurrence."
GBM, the most aggressive form of brain cancer, is estimated to have caused over 12,000 deaths in the US in 2007; and brain cancer is estimated to have caused over 39,000 deaths in Europe in 2002 (in each case the last year for which estimates are available). Beyond surgery to remove the brain tumor, and radiation therapy, there are only two treatments for GBM currently approved by the Food and Drug Administration ("FDA"). Those treatments have been shown in clinical trials to add only 10-12 weeks of survival in GBM patients. In contrast, in the two clinical trials conducted at UCLA with DCVax(R)-Brain, the patients have experienced much longer extensions of the time to disease progression (recurrence) and overall survival.
DCVax(R)-Brain is a type of personalized immunotherapy designed to stimulate a patient's own immune system to fight cancer. DCVax(R)-Brain is made up of the patient's own dendritic cells that have been "educated" to recognize and destroy cancer cells bearing the biomarkers of the patient's tumor. Each patient undergoes tumor removal through surgery as part of the current Standard of Care. Dendritic cells drawn from a sample of the patient's blood are exposed in a lab dish to the biomarkers of the patient's own tumor, and are thereby activated and "educated." These activated and "educated" dendritic cells are injected back into the patient, in a simple small injection under the skin similar to a flu shot or insulin shot, at a series of time points several weeks apart and then months apart. These dendritic cells are then able to mobilize the immune system to recognize and attack the cancer, and do so without toxicity to the patient (i.e., without grade 3 or 4 adverse events)
The Company has initiated a large Phase II clinical trial of DCVax(R)-Brain that is designed and powered to serve as a pivotal trial in support of potential product registration. The trial is currently screening and enrolling patients at a number of sites across the U.S.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.
For further information, please visit the company web site at http://www.nwbio.com
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax(R)-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings and the Risk Factors section of the Form S-1 recently filed by the Company. Finally, there may be other factors not mentioned above or included in the Company's SEC filings or recently filed Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.
http://www.nwbio.com

Copyright (C) 2008 PR Newswire. All rights reserved

[guntis]

ups

[Tiefstseetaucher]

Hier mal ein Link zu einem knapp 4 Wochen alten (englischsprachigen) Artikel über Krebs-Impfmittel, mit Ausführungen auch zu NWBO.

http://seekingalpha.com/article/64862-the-current-status-of-…



Gruß

Tiefstseetaucher

[schlitzie]

Gibt es eigentlich Informationen über die Sammelklage,die da gegen NWYA läuft ???????

[Tiefstseetaucher]

Ist ja geradezu gespenstisch still geworden hier, was aber wohl auch daran liegt, dass es kaum was Neues zu berichten gibt.

Sollte nicht eigentlich Anfang 2008 mal ein weiterer Schritt bei diesem Schweizer Projekt erfolgen?



Gruß

Tiefstseetaucher

[homertus2]

Weiß hier überhaupt jemand irgendwas?
Ihr seid ja alle so doof wie ich

[mitleser]

Antwort auf Beitrag Nr.: 33.924.311 von homertus2 am 19.04.08 02:23:44

Huhu

[Tiefstseetaucher]

Ist zwar schon 14 Tage alt, aber vielleicht haben es einige andere auch noch nicht entdeckt:

Financial Results for the Year Ended 31 December 2007


Bethesda, MD – 16 April 2008 – Northwest Biotherapeutics, Inc. (AIM:NWBS and NWBT; OTC BB: NWBO), the US-based biotechnology company focused on developing immunotherapy products for cancer, today announces its results for the year ended 31 December 2007.

Operational Highlights

* January - Phase II study, designed and powered as a pivotal trial, using DCVax®-Brain to treat Gioblastoma multiforme (GBM) initiated in the United States.
* February - Submitted application to Bundesamt für Gesundheit (BAG) in Switzerland for Authorization for Use of DCVax®-Brain in Switzerland.
* May - Secured product supply with follow-on contract with Cognate BioServices to manufacture DCVax®-Brain product.
* June - BAG Authorization granted, subject to fulfillment of certain implementation conditions.
* December - Marketing Authorization Application (MAA) submitted to Swissmedic requesting full marketing approval of DCVax®-Brain in Switzerland.
* December - Phase I/II study, funded by the Ovarian Vaccine Initiative, a private philanthropic organization, using DCVax®-L to treat recurrent ovarian cancer initiated at University of Pennsylvania.
* Strengthened management team with recruitment of Chief Financial Officer, Chief Medical Officer and Vice President of Regulatory Affairs.

Operational Highlights

* Successful initial public offering in June, listing on AIM and raising of £15 million gross proceeds.
* Eliminated debt.
* As of 31 March 2008, the Company had approximately US$ 2.2 million of cash on hand. The Company is in the process of finalizing a debt financing of up to US$ 8.0 million designed to cover its operating cash requirements until the fourth quarter of this year. It is anticipated that up to US$ 4.0 million may be available to the Company by the end of April, and the balance may become available by June.

Commenting on the results, Alton L. Boynton, Chief Executive Officer of NWBT said:

“Northwest made its debut on AIM in June 2007. Since then we have made excellent progress on many fronts including the recruitment of very experienced and highly motivated additions to the management team.

With regard to our clinical programme, we have announced encouraging data from our key DCVax®-Brain trials, the two Phase I clinical trials continuing to show very positive survival data. Of particular significance, the median survival of patients treated with DCVax®-Brain has reached 33.8 months compared to patients treated with the standard of care at 17.1 months and 8 of the 19 patients are still alive having survived for periods between 25 and 92 months.

We have also initiated two additional clinical studies, a Phase II trial in Glioblastoma multiforme, designed and powered as a pivotal trial, and a Phase I/II trial in recurrent ovarian cancer in the United States. We are rapidly building our base of clinical sites in the United States and anticipate having some 40 or more active sites by the summer.

Since June we have completed all of the implementation conditions required by Swissmedic to proceed under the BAG Authorization including establishing a Swiss subsidiary, completing the clean room at our contract manufacturer and submitting a MAA to Swissmedic.”

Detailed results are included in the Form 10-K as filed with the United States Securities and Exchange Commission (“SEC”) on April 15, 2008 and can be viewed by at http://www.rns-pdf.londonstockexchange.com/rns/4372s_-2008-4…

For further information, please contact:
Northwest Biotherapeutics
Anthony P. Deasey, Chief Financial Officer
+ 1 240 497 9024
Buchanan Communications
Lisa Baderoon ([e-mail])
/ Mary-Jane Johnson / Catherine Breen
[phone]
Collins Stewart Europe Limited
Tim Mickley / Adam Cowen
[phone]



Gruß

Tiefstseetaucher

[guntis]

Antwort auf Beitrag Nr.: 33.991.015 von Tiefstseetaucher am 29.04.08 10:33:26

wird langsam Zeit, dass sie wieder mal was von sich hören lassen

das kannte ich schon

[Tiefstseetaucher]

Also einen hab ich noch. Welche "Tragweite" diese Entscheidung hat, kann ich allerdings nicht beurteilen:

Lonza settles legal dispute with Northwest Biotherapeutics on GS Gene products
04.24.08, 3:04 AM ET


FRANKFURT (Thomson Financial) - Lonza Group AG. said Northwest Biotherapeutics Inc. agreed to destroy the GS Gene Expression system materials, made by Lonza, in its possession to end a legal dispute.

The GS Gene Expression System, owned and licensed by Lonza, is used to make therapeutic recombinant proteins and monoclonal antibodies.

[e-mail]



Immerhin sind längerwierige Rechtsstreitigkeiten damit wohl vermieden worden.

Hoffentlich klappt es bald mit der Finanzierung, die Cash-Reserven sind ja mehr als spärlich. Frage mich zudem, ob NWBO nicht längst zu einem Übernahmekandidaten geworden ist angesichts der ständigen Finanzklemme bzw. des fortdauernden Finanzierungs-Drucks. Und die Produkte sind ja immer noch ein erhebliches Stück von einer möglichen Zulassung weg.



Gruß

Tiefstseetaucher

[guntis]

Northwest Secures US$4.0 Million in Debt Financing


Last update: 2:00 a.m. EDT May 9, 2008Print E-mail RSS Disable Live Quotes

BETHESDA, Md., May 9, 2008 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:NWBO
News, chart, profile, more
Last:


Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
NWBO, , ) , today announced that Al Rajhi Holdings W.L.L. ("Al Rajhi") has entered into an agreement, executed on May 6 2008, to provide NWBT with debt financing in the amount of US$4.0 million (the "Loan").
Under the terms of the Loan, Northwest will receive US$4.0 million in return for an unsecured promissory note in the principal amount of US$4,240,000 (reflecting an original issue discount of six percent, or US$240,000). The Loan has a term of six months. Al Rajhi may elect to have the original issue discount amount paid at maturity in common stock of NWBT, at a price per share equal to the average closing price of NWBT's common stock on the NASD Over The Counter Bulletin Board over the ten trading days prior to the execution of the Loan agreement.
The Directors of the Company consider, having consulted with the Company's Nominated Adviser, Collins Stewart Europe Limited, that the Loan is fair and reasonable in the circumstances insofar as the Company's shareholders are concerned. In giving its advice to the Directors, Collins Stewart Europe Limited relied on their commercial assessment.
Alton L. Boynton, Chief Executive Officer of NWBT said:
"We are delighted to have secured this Loan from Al Rajhi. Since investing in our IPO on AIM in June 2007, Al Rajhi has accumulated a significant stake in Northwest and currently holds in excess of ten per cent of our issued and outstanding common stock. We appreciate their support for the Company and our DCVax(R) technology. The Loan will enable us to continue moving our programs forward aggressively, with minimal dilution for existing shareholders."
About NWBT
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, with limited toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.
For further information, please visit the company web site at http://www.nwbio.com.
About the Al Rajhi Group
Al Rajhi Holdings W.L.L. and Al Rajhi Partners (together "Al Rajhi") represent the business interests of Sheikh Abdulrahman Saleh Al Rajhi and his immediate family in Saudi Arabia.
Al Rajhi is a private investment company and has investments in financial services, infrastructure, mining, healthcare, biotechnology, real estate, oil and gas. Key investments include Bank Al Bilad, DanaGas, Saudi Telecom, Saudi Cement and Procare hospitals. Khalid al Rajhi, CEO of Al Rajhi, is a director of each of these companies.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward- looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks and uncertainties regarding the Company's ability to secure additional financing or raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings, including in the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and in its recently filed Form S-1. Finally, there may be other factors not mentioned above or included in the Company's SEC filings or recently filed Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.

[Tiefstseetaucher]

Und das Geld dürfte schon bald wieder knapp werden.

Thomson Financial News
Northwest Biotherapeutics Q1 loss widens on higher operating expenses
05.16.08, 5:28 AM ET





LONDON (Thomson Financial) - Northwest Biotherapeutics Inc. said its first-quarter loss widened due to higher operating expenses, including research and development costs and administrative expenses.

The U.S.-based biotech company said for the first quarter ended March, its net loss widened to $5.63 million from $1.95 million, while operating expenses increased to $5.69 million from $1.82 million, a year ago.

The company's research and development costs increased to $3.06 million from $1.31 million, and general and administrative expenses grew to $2.63 million from $511,000.



Gruß

Tiefstseetaucher

[mitleser]

Antwort auf Beitrag Nr.: 34.113.477 von Tiefstseetaucher am 16.05.08 19:10:53

na dann können Sie ja bald günstig übernommen werden.

[Tiefstseetaucher]

Antwort auf Beitrag Nr.: 34.113.537 von mitleser am 16.05.08 19:18:45

Ein "kleiner" Aufschlag von 50 bis 80 Prozent auf den aktuellen Kurs sollten schon drin sein.

(Daran glauben tu ich aber nicht.)




Gruß

Tiefstseetaucher

[mitleser]

Antwort auf Beitrag Nr.: 34.113.629 von Tiefstseetaucher am 16.05.08 19:33:10

dann müssen die da irgendwie durch.

Haben ja hoffnungsvolle Produkte

'ne Kooperation mit 'nem großen wäreauch nicht schlecht.

[Tiefstseetaucher]

Kleiner, nicht uninteressanter Beitrag zu DVax aus Sicht einer Patientin:

http://www.nydailynews.com/ny_local/2008/05/27/2008-05-27_sh…


Vielleicht kommt ja so langsam doch wieder mal Bewegung in den Wert.


Gruß


Tiefstseetaucher

[Tiefstseetaucher]

Es gibt auch noch einige andere Berichte in den amerikanischen Medien in denen DCVax genannt wird, größtenteils wohl anlässlich der Erkrankung von Herrn Kennedy.



Gruß

Tiefstseetaucher

[mitleser]

Antwort auf Beitrag Nr.: 34.180.078 von Tiefstseetaucher am 27.05.08 15:34:17

passieren tut trotzdem nix.

einfach gar nix mehr.

Nur noch tote Hose hier.

Die Fantasie schwindet auch immer mehr.

Zumindestens meine.

Jemand optimistischer als ich???

[guntis]

Antwort auf Beitrag Nr.: 34.228.103 von mitleser am 03.06.08 16:50:30

interessieren würde mich wieso heute so viel gehandelt wird

so viel hatten wir schon seit vielen Monaten nicht mehr

vielleicht kommt gerade jetzt was

[sellongoodnews]

Northwest Secures US$4.0 Million in Debt Financing
BETHESDA, Md., May 9 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO), today announced that Al Rajhi Holdings W.L.L. ('Al Rajhi') has entered into an agreement, executed on May 6 2008, to provide NWBT with debt financing in the amount of US$4.0 million (the 'Loan').

Under the terms of the Loan, Northwest will receive US$4.0 million in return for an unsecured promissory note in the principal amount of US$4,240,000 (reflecting an original issue discount of six percent, or US$240,000). The Loan has a term of six months. Al Rajhi may elect to have the original issue discount amount paid at maturity in common stock of NWBT, at a price per share equal to the average closing price of NWBT's common stock on the NASD Over The Counter Bulletin Board over the ten trading days prior to the execution of the Loan agreement.

The Directors of the Company consider, having consulted with the Company's Nominated Adviser, Collins Stewart Europe Limited, that the Loan is fair and reasonable in the circumstances insofar as the Company's shareholders are concerned. In giving its advice to the Directors, Collins Stewart Europe Limited relied on their commercial assessment.

Alton L. Boynton, Chief Executive Officer of NWBT said:

'We are delighted to have secured this Loan from Al Rajhi. Since investing in our IPO on AIM in June 2007, Al Rajhi has accumulated a significant stake in Northwest and currently holds in excess of ten per cent of our issued and outstanding common stock. We appreciate their support for the Company and our DCVax(R) technology. The Loan will enable us to continue moving our programs forward aggressively, with minimal dilution for existing shareholders.'

About NWBT

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, with limited toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

About the Al Rajhi Group

Al Rajhi Holdings W.L.L. and Al Rajhi Partners (together 'Al Rajhi') represent the business interests of Sheikh Abdulrahman Saleh Al Rajhi and his immediate family in Saudi Arabia.

Al Rajhi is a private investment company and has investments in financial services, infrastructure, mining, healthcare, biotechnology, real estate, oil and gas. Key investments include Bank Al Bilad, DanaGas, Saudi Telecom, Saudi Cement and Procare hospitals. Khalid al Rajhi, CEO of Al Rajhi, is a director of each of these companies.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'expects,' 'believes,' 'intends,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward- looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks and uncertainties regarding the Company's ability to secure additional financing or raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission ('SEC') filings, including in the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and in its recently filed Form S-1. Finally, there may be other factors not mentioned above or included in the Company's SEC filings or recently filed Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE Northwest Biotherapeutics, Inc.



Source: PR Newswire (May 9, 2008 - 2:00 AM EDT)

News by QuoteMedia

[Tiefstseetaucher]

Nach längerer Zeit mal wieder ein etwas größerer Umsatz heute (in USA), und dann auch noch bei steigendem Kurs. Gibt es irgendwelche News?



Gruß

Tiefstseetaucher

[guntis]

Antwort auf Beitrag Nr.: 34.283.105 von Tiefstseetaucher am 11.06.08 17:03:26

nein, kann auch keine News finden

kannst dich wieder hin legen

[Tiefstseetaucher]

Mal wieder ein Zeitungs-Artikel zu DCVax.

http://www.orlandosentinel.com/services/newspaper/printediti…


Besonders gefällt mir natürlich der Satz:

"I've never seen a clinical trial that's had this promise," says Gruber, who is medical director of the Brain Tumor Center of New Jersey at Overlook.


Bleibt nur zu hoffen, dass sich die Daten der laufenden Studien weiterhin bestätigen und dass das Geld auch ausreicht, um das ganze bis zum erfolgreichen Ende durchzustehen.


Gruß

Tiefstseetaucher

[Tiefstseetaucher]

Irgendjemand noch eine Meinung zu dieser Aktie?

Habe neulich in einem Blog gelesen, dass man sich bei NWBO um eine Finanzierung für den Rest des Jahres bemüht. Ansonsten hab ich keine neuen Infos.

Der Kursabsturz der letzten Tage dürfte wohl eine Spätfolge des miesen allgmeinen Umfelds sein, ärgerlich ist er allemal.

Andererseits gibts bei dieser Aktie aber ohnehin wohl nur Top oder Flop.


Gruß

Tiefstseetaucher

[guntis]

Antwort auf Beitrag Nr.: 34.539.898 von Tiefstseetaucher am 18.07.08 17:48:34

ja diese

Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Highlights Include Clinical Trial Updates

Last update: 2:00 a.m. EDT July 18, 2008
BETHESDA, Md., July 18, 2008 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:northwest biotherapeutics in com new
News, chart, profile, more
Last: 1.83+0.13+7.65%

3:41pm 07/18/2008

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
NWBO 1.83, +0.13, +7.7%) , (the "Company or NWBT"), today announced that Dr. Alton L. Boynton, its President and Chief Executive Officer, will deliver a presentation updating the Company's progress in the development of dendritic vaccines for the treatment of cancer, at the "Next Generation Vaccines" conference. The conference will be held on 17 &18 July, at the Gaylord National Resort and Convention Center in National Harbor, Maryland, USA. Dr. Boynton is scheduled to present as part of the Advances in Cancer Vaccines session on July 18th @ 11:15 am EST.
Dr. Boynton will provide an update on NWBT's product candidates, including therapeutic cancer vaccines DCVax(R)-Brain for the treatment of Glioblastoma multiforme and DCVax(R)-Prostate for hormone-independent prostate cancer.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started a Phase I/II trial with DCVax(R) directed to ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.
For further information, please visit the company web site at http://www.nwbio.com
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in the Phase II trial of DCVax(R)-Brain and complete the trial on a timely basis, risks related to meeting the clinical endpoints in the planned Phase II clinical trial of DCVax(R)-Brain, risks related to manufacturing, risks related to the Company's ability to initiate, and enroll patients in, the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax(R)-Prostate or DCVax(R)-Brain will demonstrate safety and efficacy, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
http://www.nwbio.com

Copyright (C) 2008 PR Newswire. All rights reserved

[Tiefstseetaucher]

Antwort auf Beitrag Nr.: 34.549.022 von guntis am 21.07.08 10:44:25

Gute Neuigkeiten scheint der Mann ja leider nicht vermeldet zu haben, wenn man den heutigen Kursverlauf zum Maßstab nimmt.



Gruß

Tiefstseetaucher

[HeinzBork]

Was denn nun los?
Stop loss fischen oder macht die Firma die Grätsche?
Nirgends was zu finden.

[Tiefstseetaucher]

Antwort auf Beitrag Nr.: 34.780.561 von HeinzBork am 20.08.08 17:50:49

Mittlerweile gibt es die Erklärung:

Höchste Geldnot. Von Toucan gabs zwar nochmals ne Finanzspritze von 1 Mio. Dollar, aber das reicht auch nur noch 5 Wochen. Jetzt muss dringend neues Geld her, aber ob die begonnen Verhandlungen erfolgreich verlaufen, bleibt abzuwarten.

Sieht m.E. nicht gut aus, denn die Studien benötigen allesamt noch lange Zeit und es wird daher entsprechend viel Geld benötigt.

http://www.forbes.com/afxnewslimited/feeds/afx/2008/08/20/af…


Gruß

Tiefstseetaucher

[HeinzBork]

Antwort auf Beitrag Nr.: 34.782.840 von Tiefstseetaucher am 20.08.08 20:14:24

Danke Dir.
Na dann seh ich ja eher schwarz.

[Tiefstseetaucher]

Jetzt auch noch eher schlechte Nachrichten von einem Konkurrenten. Cell Genesys musste eine Phase-III-Studie zu einem ähnlichen Impfmittel (GVAX) bei Prostatakrebs abbrechen. Bei der Kombination mit Chemo traten mehr Todesfälle als in der Kontrollgruppe (nur Chemo) auf. Der Kurs brach darauf hin um über 70 Prozent ein.

Also selbst wenn das Finanzierungsproblem gelöst wird, bleibt hier ein erhebliches Risiko.




Gruß

Tiefstseetaucher

[guntis]

Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain


Last update: 2:00 a.m. EDT Sept. 11, 2008
BETHESDA, Md., Sept 11, 2008 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:northwest biotherapeutics in com new
News, chart, profile, more
Last: 1.35+0.15+12.50%

11:54am 09/10/2008

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
NWBO 1.35, +0.15, +12.5%) ("NWBT" or the "Company") today announced the most recent long-term follow-up data, through June 15, 2008, from its prior Phase I and Phase I/II clinical trials with DCVax(R)-Brain, which began in 2000 and 2003, for patients with Glioblastoma multiforme, the most lethal type of brain cancer. This long-term data shows that 84% of patients who received DCVax(R)-Brain in these trials have so far lived longer than the median survival of 14.6 months under standard of care, 68% of the patients have so far lived more than 2 years, 58% of the patients have so far lived more than 2-1/2 years, 42% have so far lived more than 3 years, and 26% have so far lived more than 4 years, with patients surviving as long as 8 years to date. The median survival in the patients from these trials is now 36.4 months, under a standard Kaplan Meier analysis.
DCVax(R)-Brain is a groundbreaking personalized vaccine that takes a patient's own immune cells and trains them in the laboratory to attack the biomarkers from that patient's own tumor cells. The 10-day manufacturing process produces several years of personalized vaccine for a patient, making DCVax(R)-Brain an "off-the-shelf" product for that patient throughout the treatment period. DCVax(R)-Brain is administered as a simple injection under the skin, similar to a flu shot, and is not toxic as chemotherapies are.
The most recent data provides an update for the period since December 31, 2007, concerning both disease progression and overall survival. During that period, only one of the nineteen patients experienced disease progression (at 59.5 months), and only one patient died (at 37.8 months).
The long term data from these clinical trials shows that more than 80% of the patients who received DCVax(R)-Brain showed a clinical response. In contrast, the typical response rates for cancer drugs are in the range of 20 to 25% of patients, and have been as low as 13% of patients with some approved cancer drugs.
DCVax(R)-Brain is now in a large, Phase II clinical trial designed and powered as a pivotal trial, which is currently enrolling patients at 11 medical centers across the U.S. (listed at http://www.nwbio.com).
Two leading physicians participating in the trial had the following to say:
"For the first time in the fight against cancer, we are not using a toxic approach to treatment. DCVax(R)-Brain uses patients' own immune cells and own tumor material, and does not cause the kinds of toxic side effects seen with typical cancer treatments. DCVax-Brain is helping lead the way to new patient- friendly treatment approaches," said Dr. Michael Gruber, Clinical Professor of Neurology and Neurosurgery, NYU Cancer Institute in New York and Overlook Hospital in New Jersey, two of 11 sites of the clinical trial.
"The ongoing results from the prior clinical trials with DCVax(R)-Brain continue to be very encouraging and exciting. This experimental treatment is breaking new ground in the extension of patients' survival with the most lethal form of brain cancer. This revolutionary approach may allow our patients to live longer, healthier, productive lives," said Dr. Steven Brem, Chief, Neuro-Oncology and Director of Neurosurgery at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL, another active site in the clinical trial.
Since 2005, the standard of care for patients with newly diagnosed GBM has been surgery followed by a combination of radiation and Temodar(R). The studies defining this standard of care achieved a median time to progression of 6.9 months and a median overall survival of 14.6 months (Stupp, et. al., N Engl J Med, 352:987, 2005, n = 573). Further data from UCLA has demonstrated a somewhat longer median time to progression of 8.1 months, and median overall survival of 17.0 months, in selected patients with GBM who received the same standard of care (n = 119).
In comparison, the long-term follow-up data as of June 15, 2008, for patients who received DCVax(R)-Brain in the two prior clinical trials is now as follows:
-- The median overall survival in patients from these two trials is now 36.4 months, as determined by standard Kaplan Meier analysis;
-- The median time to disease progression (tumor recurrence) is now 18.1 months;
-- 90% of the patients for these trials patients have surpassed the standard of care median time to progression of 6.9 months;
-- 84% of the patients have surpassed the standard of care median overall survival time of 14.6 months;
-- To date, 68% of patients receiving DCVax(R)-Brain in addition to standard of care have lived longer than two years, 58% have lived longer than 2 1/2 years, 42% have lived longer than three years, and 26% have lived longer than four years;
Dr. Alton L. Boynton, President and Chief Executive Officer of NWBT commented, "We continue to be encouraged by the long-term survival data of the patients treated in these studies, which suggest that treatment with DCVax(R)- Brain has the potential to more than double the time to tumor recurrence, and more than double survival time for patients suffering from this dreadful disease."
GBM, the most aggressive form of brain cancer, is estimated to have caused more than 12,000 deaths in the United States in 2007; and brain cancer is estimated to have caused over 39,000 deaths in Europe in 2002 (in each case, the last year for which estimates are available). Beyond surgery to remove the brain tumor and radiation therapy, there are only two treatments for GBM patients currently approved by the U.S. Food and Drug Administration ("FDA"). Those treatments have been shown in clinical trials to typically add only 10-12 weeks of survival in GBM patients.
As noted above, DCVax(R)-Brain is a personalized immunotherapy designed to stimulate a patient's own immune system to fight cancer. DCVax(R)-Brain is made up of the patient's own "dendritic cells," the master cells of the immune system, that have been "educated" to recognize and destroy cancer cells bearing the biomarkers of the patient's own tumor. Each patient undergoes tumor removal through surgery as part of the current Standard of Care. Dendritic cells drawn from a sample of the patient's blood are exposed in a lab dish to the biomarkers of the patient's own tumor, along with certain other proprietary steps, and are thereby activated and "educated." These activated and "educated" dendritic cells are injected back into the patient, in a simple small injection under the skin, similar to a flu shot or insulin shot, at a series of time points several weeks apart and then months apart. These dendritic cells are then able to mobilize the immune system to recognize and attack the cancer, and do so without toxicity to the patient (i.e., without grade 3 or 4 adverse events).
Financials
The Company previously announced on August 20, 2008, that it had approximately $1.1 million of cash on hand. The Company estimates that its available cash is sufficient to support its day to day operations through to the end of September 2008. It therefore needs to raise significant additional capital to fund its clinical trials and other operating activities and to repay indebtedness. The Company continues to be in late stage discussions with several parties in regard to additional financing transactions. Shareholders should be aware that if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company financial position and operations.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.
For further information about clinical sites and Company information please visit the company web site at http://www.nwbio.com.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax(R)-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings and the Risk Factors section of the Form S-1 recently filed by the Company. Finally, there may be other factors not mentioned above or included in the Company's SEC filings or recently filed Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.
http://www.nwbio.com

Copyright (C) 2008 PR Newswire. All rights reserved

[mitleser]

Antwort auf Beitrag Nr.: 35.059.029 von guntis am 11.09.08 09:35:35

Leben wir eigentlich noch???

Noch Jemand da?

[guntis]

also leben tu ich noch

[mitleser]

Antwort auf Beitrag Nr.: 36.564.540 von guntis am 12.02.09 12:27:12

Mit "Leben wir noch" meinte ich unser Baby.

Aber schön, dass noch Jemand da ist.

[mitleser]

Antwort auf Beitrag Nr.: 36.564.648 von mitleser am 12.02.09 12:39:15

Gibt's eigentlich was Neues?

Weißt Du was?

[guntis]

Antwort auf Beitrag Nr.: 36.564.740 von mitleser am 12.02.09 12:50:14

Northwest Biotherapeutics Secures $700,000 Equity Financing


Last update: 2:00 a.m. EST Feb. 10, 2009
BETHESDA, Md., Feb 10, 2009 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:northwest biotherapeutics in com new
News , chart , profile , more
Last: 0.67+0.25+59.52%

12:48pm 02/17/2009

Delayed quote dataAdd to portfolio
Analyst
Create alert Insider
Discuss
Financials
Sponsored by:
NWBO 0.67, +0.25, +59.5%) (the "Company") announces today receipt of $700,000 in cash from Al Rajhi Holdings through the subscription of 1,000,000 new shares in the form of the Company's common stock at $0.70 per share. The new stock is expected to be admitted to trading on AIM on 16 February 2009. The shares will not be tradable on the Company's OTC bulletin board listing in the US without prior registration. The proceeds will be used to support the Company's ongoing working capital needs.
"We are very pleased to have completed another interim financing despite severely adverse general market conditions," said NWBT's Chief Executive Officer Alton Boynton. "We look forward to continuing the financing discussions currently under way with several additional parties for short-term and long-term funding of the Company".
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.
For further information, please visit the company web site at http://www.nwbio.com.
Disclaimer
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.

[guntis]

Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival


Last update: 2:00 a.m. EST Feb. 17, 2009
BETHESDA, Md., Feb 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBO:northwest biotherapeutics in com new
News , chart , profile , more
Last: 0.67+0.25+59.52%

12:48pm 02/17/2009

Delayed quote dataAdd to portfolio
Analyst
Create alert Insider
Discuss
Financials
Sponsored by:
NWBO 0.67, +0.25, +59.5%) ("NWBT" or the "Company") today announced further long-term follow-up data, for the second half of 2008, from its prior Phase I and Phase I/II clinical trials with DCVax(R)-Brain in patients with Glioblastoma multiforme, the most rapid and lethal type of brain cancer. During the update period from June 15, 2008, through January 1, 2009, none of the twenty patients treated with standard of care plus DCVax(R)-Brain died. So far, now, 68% of patients treated with DCVax(R)-Brain have lived more than 2 years, 63% have lived more than 2-1/2 years, 53% have lived more than 3 years, 35% have lived more than 4 years and 25% have lived more than 5 years. In contrast, patients who receive full standard of care (surgery, radiation and chemotherapy) without DCVax(R)-Brain have a median survival of only 14.6 months, and less than 5% of these patients are typically alive at 5 years.
In addition to there being no deaths among the DCVax(R)-Brain treated patients during the 2008 update period, only two of the twenty patients experienced progression (recurrence) of their brain cancer. One of these two patients had been disease free for nearly 6 years (70 months) at the time of their progression, and the other patient had been disease free for more than 4 years (50 months). In contrast, the usual time to progression (recurrence) in GBM, with full standard of care treatment but without DCVax(R)-Brain, is only 6.9 months.
In other results from the 2008 update data period:

-- 95% of DCVax(R)-Brain treated patients have lived longer than the
median survival of 14.6 months with existing standard of care
treatment;
-- Likewise, 95% of DCVax(R)-Brain treated patients have been free of
disease progression (recurrence) for longer than the median progression
free survival of 6.9 months with existing standard of care treatment.



DCVax(R)-Brain is a groundbreaking personalized vaccine that takes a patient's own master immune cells and the biomarkers from that patient's own tumor tissue, and activates the master immune cells so they can mobilize the full immune system to recognize and kill the tumor cells. The 10-day manufacturing process produces several years of personalized vaccine for a patient, making DCVax(R)-Brain an "off-the-shelf" product for that patient throughout the treatment period. DCVax(R)-Brain is administered as a simple injection under the skin, similar to a flu shot, and is not toxic as most chemotherapies are.
DCVax(R)-Brain is now in a large Phase II clinical trial which is currently enrolling patients at 11 medical centers across the U.S. (listed at http://www.nwbio.com).
"The long-term survival of patients treated with DCVax(R)-Brain continues to be quite striking and encouraging," commented Dr. Alton L. Boynton, President and Chief Executive Officer of NWBT, "and it is especially exciting that this long-term survival is without toxicity, enabling our patients to go on with their lives in a normal fashion."
GBM, the most aggressive form of brain cancer, is estimated to have caused more than 12,000 deaths in the United States in 2007; and brain cancer is estimated to have caused over 39,000 deaths in Europe in 2002 (in each case, the last year for which estimates are available). Beyond surgery to remove the brain tumor and radiation therapy, there are only two treatments for GBM patients currently approved by the U.S. Food and Drug Administration ("FDA"): one chemotherapy drug, and one drug-infused wafer for surgical implant. Those treatments have been shown in clinical trials to typically add only 10-12 weeks of survival in GBM patients.
Since 2005, the standard of care for patients with newly diagnosed GBM has been surgery followed by a combination of radiation and Temodar(R). The studies that defined this standard of care, and formed the basis for the approval of Temodar(R), achieved a median overall survival of 14.6 months and a median time to disease progression (recurrence) of 6.9 months (Stupp, et. al., N Engl J Med, 352:987, 2005, n = 573).
As noted above, DCVax(R)-Brain is a personalized immunotherapy designed to stimulate a patient's own immune system to fight cancer. DCVax(R)-Brain is made up of the patient's own "dendritic cells," the master cells of the immune system, that have been activated and "educated" to mobilize the full immune system to recognize and destroy cancer cells bearing the biomarkers of the patient's own tumor. Each patient undergoes tumor removal through surgery as part of the current standard of care. Dendritic cells drawn from a sample of the patient's blood are exposed in a lab dish to the biomarkers of the patient's own tumor, along with certain other proprietary steps, and are thereby activated and "educated." These activated and "educated" dendritic cells are injected back into the patient, in a simple small injection under the skin, similar to a flu shot or insulin shot, at a series of time points several weeks apart and then months apart. These dendritic cells are then able to mobilize the immune system to recognize and attack the cancer, and do so without toxicity to the patient (i.e., without grade 3 or 4 adverse events).
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is currently open and enrolling patients at 11 sites across the U.S. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.
For further information about clinical sites and Company information please visit the company web site at http://www.nwbio.com.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax(R)-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings and the Risk Factors section of the Form S-1 recently filed by the Company. Finally, there may be other factors not mentioned above or included in the Company's SEC filings or recently filed Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.
http://www.nwbio.com

[Tiefstseetaucher]

Ist schon etwas merkwürdig, dass das Unternehmen trotz dieser (scheinbar?) so sensationellen Zahlen immer noch kurz vor der Pleite steht und sich nur von Monat zu Monat mit neuen Krediten und Aktienoptionen über Wasser hält.

Anscheinend traut sich keines der größeren Unternehmen an den Impfstoff-Ansatz. Vielleicht ändert sich das, falls Dendreon mit seinem Prostata-Wirkstoff demnächst eine positive Phase III präsentieren kann.

Als Biotech-Laie muss man sich schon wundern, dass hier bei NWBO so wenig passiert. Ich wäre jedenfalls äußerst an dieser Art der Behandlung interessiert, wenn ich an dieser Krankheit erkrankt wäre.


Gruß

Tiefstseetaucher

[03482]

Ich schließe mich der Meinung von Tiefseetaucher an:
Es gibt - glaube ich als Laie - extrem positive Nachrichten und es passiert wenig...
Sind diese Resultate "nichts wert" oder dauert der Kommunikationsfluss solange, bis er die richtigen Leute erreicht ?

[guntis]

mich würde mal eine qualifizierte Schätzung interessieren wie lange das noch dauern kann bis sie eine Genehmigung bekommen

ich befürchte leider, dass das noch viele Monate dauert und ob sie das mit der Finazierung so lange hin bekommen ist vermutlich die Frage schlechthin

[praslin0808]

hab schreiben von meiner bank das ich gegen
northwest bio an sammelklage teilnehmen kann

weiss jemand von euch dazu mehr?

[Sieben**]

Antwort auf Beitrag Nr.: 36.851.148 von praslin0808 am 26.03.09 10:32:34

nwbo erhält am 07.04. 1,1 Millionen Dollar Finanzspritze, Meldung einsehbar unter "pinksheets.com": "news"

[guntis]

[Tiefstseetaucher]

Antwort auf Beitrag Nr.: 36.965.663 von guntis am 14.04.09 16:12:30

Das ist wohl der Provenge-Effekt. Jetzt heißt es abwarten, ob dieser Effekt bei NWBO zu einer tatsächlichen Veränderung der Lage führt. Etwa in Form eines neuen Groß-Investors oder eines Kaufinteressenten.


Gruß


Tiefstseetaucher

[guntis]

Antwort auf Beitrag Nr.: 36.966.708 von Tiefstseetaucher am 14.04.09 18:25:12

sorry - aber was ist bitte ein Provenge-Effekt

[Tiefstseetaucher]

Antwort auf Beitrag Nr.: 36.967.144 von guntis am 14.04.09 19:24:14

Provenge ist ein anderes "Impfmittel" gegen Krebs, das von der Firma Dendreon entwickelt wird. Die haben heute bekannt gegeben, dass eine Phase III-Studie zu diesem Wirkstoff erfolgreich gewesen sein soll.

Damit wäre nach etlichen Rückschlägen erstmals eine Zulassung für einen solchen Impfstoff gegen Krebs, im Falle von Provenge Prostata-Krebs, möglich.

Allerdings sollen die genauen Zahlen zur Studie erst Ende des Monats bekannt gegeben werden. Und dann muss ja auch noch die FDA zustimmen.


Gruß

Tiefstseetaucher

[guntis]

Antwort auf Beitrag Nr.: 36.968.638 von Tiefstseetaucher am 14.04.09 23:12:40

mir wäre lieber NWBO würde mal solch eine Meldung machen

trotzdem danke für die Info